Ainos, Inc.

Ainos, Inc. (AIMD) is a publicly traded US company. Ainos Inc is a dual-platform company advancing artificial intelligence based smelltech technologies and immune therapeutics. Its primary strategic focus is the commercialization of its proprietary scent digitization platform, AI Nose, while the company also continue to develop therapeutic assets based on its low-dose oral interferon program, VELDONA. Its core technology platform, AI Nose, is an AI-based electronic olfaction system that integrates gas sensor arrays with proprietary artificial intelligence models, which it refers to as a smell language model (SLM), to digitize scent and volatile organic compound (VOC) signals into Smell ID, a machine-readable data format.

The company reports trailing twelve-month revenue of $161 and net loss of $2.46M.

Key metrics include a return on equity of -43.2%, a debt-to-equity ratio of 2.88.

Investors tracking AIMD can follow price movements, analyst estimates, and fundamental changes directly through FINOTAUR's research tools.